| Elimusertib studied in …STUDIED_INderived10 of 10 |
|---|
| → studied in | NCT04514497Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer · 10 trials list this drug (6 active) | — | — | Malignant Solid Neoplasm,Malignant Lung Neoplasm,Malignant Pancreatic Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04535401Phase 1 · active not recruiting Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines · 10 trials list this drug (6 active) | — | — | Digestive System Carcinoma,Gastric Carcinoma,Colorectal Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04576091Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer · 10 trials list this drug (6 active) | — | — | Malignant Lip and Oral Cavity Neoplasm,Malignant Sinonasal Neoplasm,Head and Neck Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04491942Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer · 10 trials list this drug (6 active) | — | — | Malignant Solid Neoplasm,Breast Carcinoma,Head and Neck Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04616534Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors · 10 trials list this drug (6 active) | — | — | Malignant Solid Neoplasm,Malignant Pancreatic Neoplasm,Primary Peritoneal Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05071209Phase 1/Phase 2 · active not recruiting Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors · 10 trials list this drug (6 active) | — | — | Lymphoma,Malignant Solid Neoplasm,Ewing Sarcoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04095273Phase 1 · completed Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug · 10 trials list this drug (6 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04267939Phase 1 · terminated ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer · 10 trials list this drug (6 active) | — | — | Solid Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03188965Phase 1 · completed First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas · 10 trials list this drug (6 active) | — | — | Solid Neoplasm,Non-Hodgkin Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05010096Phase 1 · withdrawn BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors · 10 trials list this drug (6 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |